Skip to content
10-Q

Quarterly Report

IOVANCE BIOTHERAPEUTICS, INC. IOVA

0001558370-25-007009

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 333.93M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $188.05M
Short Term Investments Q1 2025 · Dec 31, 2024 $208.09M
Current Liabilities Q1 2025 · Mar 31, 2025 $122.69M
Current Liabilities Q1 2025 · Dec 31, 2024 $122.34M
Total Liabilities Q1 2025 · Mar 31, 2025 $198.88M
Total Liabilities Q1 2025 · Dec 31, 2024 $200.02M
Current Assets Q1 2025 · Mar 31, 2025 $512.65M
Current Assets Q1 2025 · Dec 31, 2024 $457.02M
Total Assets Q1 2025 · Mar 31, 2025 $966.74M
Total Assets Q1 2025 · Dec 31, 2024 $910.43M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $115.69M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $134.19M
Shares Diluted restated Q1 2025 · Mar 31, 2024 266.22K sh
Capex Q1 2025 · Mar 31, 2024 $4.17M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$122.28M
Stockholders Equity Q1 2025 · Mar 31, 2024 $680.02M
Stockholders Equity Q1 2025 · Dec 31, 2023 $584.61M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.42
Eps Basic Q1 2025 · Mar 31, 2024 −$0.42
Sga Expense Q1 2025 · Mar 31, 2024 $31.39M
Rd Expense Q1 2025 · Mar 31, 2024 $79.78M
Net Income Q1 2025 · Mar 31, 2024 −$112.98M
Operating Income Q1 2025 · Mar 31, 2024 −$117.72M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $7.26M
Revenue Q1 2025 · Mar 31, 2024 $715K